2. Academic Validation
  3. Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19

  • Antimicrob Agents Chemother. 2022 Dec 15;e0135322. doi: 10.1128/aac.01353-22.
Elizabeth E Zumbrun 1,  Chengzi I Kaku 2,  Lukas Dillinger 3,  Samantha E Zak 1,  Ana I Kuehne 1,  Russel R Bakken 1,  Jeffrey W Koehler 1,  Korey L Delp 1,  Christopher P Stefan 1,  Raina Kumar 1,  Jeffrey R Kugelman 1,  Alicia M Moreau 1,  Xiankun Zeng 1,  John M Dye 1,  Andrew S Herbert 1,  Kristin Narayan 3,  Laura M Walker 3
Affiliations

Affiliations

  • 1 U.S. Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.
  • 2 Adimab LLC, Lebanon, New Hampshire, USA.
  • 3 Invivyd, Inc., Waltham, Massachusetts, USA.
PMID: 36519929 DOI: 10.1128/aac.01353-22
Abstract

Adintrevimab is a human immunoglobulin G1 monoclonal antibody engineered to have broad neutralization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and other SARS-like coronaviruses with pandemic potential. In both Syrian golden hamster and rhesus macaque models, prophylactic administration of a single dose of adintrevimab provided protection against SARS-CoV-2/WA1/2020 Infection in a dose-dependent manner, as measured by significant reductions in lung viral load and virus-induced lung pathology, and by inhibition of viral replication in the upper and lower respiratory tract.

Keywords

ADG20; COVID-19; SARS-CoV-2; adintrevimab; animal model; monoclonal antibody; preclinical; prevention.

Figures
Products